Bronwyn has over 25 years experience in the Medtech and life science industries. She has lived and worked in both Sweden and Spain and she also spent part of career working in women’s health at Medtronic where she first started to track the progress and success of the Vitrolife Group.
Excellence in reproductive health
Dedicated to the reproductive-health market since 1994, we have grown by focusing on product development, groundbreaking research, consistent quality control and acquisitions of innovative companies in the industry. Based on science and advanced research capabilities, our aim is to deliver products and services for the entire reproductive-health journey, providing consistent performance and guaranteed quality.
Our solutions enable optimised procedures and workflow efficiency, helping clinics to deliver outstanding results. The Vitrolife Group represents a competitive and profitable business with the best trained staff and optimal solutions for patient needs.
We take a holistic approach to reproductive health where we provide training, support and a wide range of services for clinics and laboratories worldwide. We are recognised as a leading knowledge provider in the industry as we work with both universities, research institutes, networks and communities to secure and improve successful treatment outcomes.
We are very proud to deliver cutting edge solutions to clinics enabling people around the world to fulfil their dream of having a healthy baby.
Meet our CEO
Bronwyn Brophy
The Vitrolife Group in figures
We contribute to successful treatment outcomes by providing assisted reproductive technologies, primarily to IVF clinics.
EMPLOYEES
~1,100
SALES IN 2023
3,512
MSEK
GLOBAL PRESENCE
~125
Markets
Vision with a purpose
Enable people to fulfill the dream of having a healthy baby
Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients.
Sustainable profitable growth
Long-term growth and profit-targets - 5 years
Annual organic revenue growth
(in local currencies)
>10%
EBITDA margin
> 33%
Net debt/EBITDA
< 3
Outcome 2023
Annual organic revenue growth
(in local currencies)
*Excluding discontinued business
5%*
EBITDA margin
32.3%
Net debt/EBITDA
1.0
Vitrolife Group committed to deliver sustainable profitable growth
Focus on five strategic priorities:
Ensure sustainability in everything we do:
Transversal to these priorities, it is our commitment to ensure sustainability in everything we do.
Learn more on our sustainability approach
Our values
The corporate values of Vitrolife Group are a guide for how to act and make decisions in different situations. This way, all colleagues turn the shared values into a strong company culture across the organisation. Every day and together.
Integrity
It’s in our DNA to always do what is right
Quality
Quality all the way, in everything that we do
Innovation
Pushing the boundaries of creativity & science to improve patient outcomes
Collaboration
Together, we are dedicated to making a difference in reproductive health
Vitrolife Group
For decades of innovation, we have made a difference
Our passion and commitment to making a difference in reproductive health has never been stronger.
